Condition
Thymalfasin
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Withdrawn3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT02535988Phase 2Withdrawn
Abscopal Effect for Metastatic Colorectal Cancer
NCT02542930Phase 2Withdrawn
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
NCT02542137Phase 2Withdrawn
Abscopal Effect for Metastatic Small Cell Lung Cancer
NCT02545751Phase 2Unknown
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Showing all 4 trials